News

John Theurer Cancer Center Enrolls First Patients for Groundbreaking Phase II Clinical Trial for Glioblastoma

Physicians at the John Theurer Cancer Center have enrolled the first two patients nationwide in an international phase II clinical trial of Kazia Therapeutics’s novel therapy, GDC-0084, for glioblastoma. Glioblastoma (GBM) is the most common and aggressive form of primary brain cancer, with limited available FDA-approved treatments and a median survival of only 15 months from diagnosis. About 12,500 patients in the US are diagnosed with GBM each year, including Senator John McCain, who recently passed away from the disease.

READ FULL ARTICLE ON RDMAG.COM